Development of resistance to targeted molecular therapy in metastatic colorectal carcinomas carrying the BRAF V600E mutation (PARTACER-Switzerland)

In this study, patients with metastatic colorectal cancer with a proven BRAF V600E mutation receive targeted therapy with the drugs cetuximab and encorafenib.

Study objective

The objective of this study is to explore the biological mechanisms that lead to the development of resistance to targeted therapies in patients with advanced colorectal cancer harboring the BRAF mutation. By comparatively analyzing tumor, blood, and stool samples before treatment initiation and during disease progression, as well as through production of organoids, we aim to better understand why treatment with cetuximab and encorafenib loses its effectiveness over time. This knowledge should contribute to the development of more effective and personalized therapeutic approaches in the future.

Who can take part?

Patients who have metastatic colorectal cancer with evidence of the BRAF V600E mutation.